Results 81 to 90 of about 20,877 (183)

Exploring Risks of Adverse Drug Events From Single Drug to Three‐Drug Combination

Clinical and Translational Science, Volume 19, Issue 8, August 2026.
ABSTRACT Use of three‐drug combinations is common and could increase the risk of adverse drug events (ADEs). Signals of ADEs from three‐drug combinations could be identified from real‐world data, and the risks of ADEs from single drug exposure to three‐drug combination exposure could be illustrated by a graphic model.
Yi Shi, Anna Sun, Chien‐Wei Chiang, Yuedi Yang, Katherine M. Hunold, Jing Xu, Mu Shan, Allison Lu, Massimiliano Russo, Jeffrey M. Caterino, Michael T. Eadon, Lang Li, Jing Su, Macarius Donneyong, Pengyue Zhang   +14 more
wiley   +1 more source

Pharmacology of allopurinol [PDF]

Arthritis & Rheumatism, 1975
openaire   +2 more sources

Allopurinol use and risk of acute coronary syndrome in gout patients: a population-based cohort study in Sweden

BMJ Open
Objectives To investigate the impact of allopurinol use on the risk of first-ever acute coronary syndrome (ACS) event in patients with gout.Methods Using national and regional register data, we included all patients with a gout diagnosis at primary or ...
Ulf Lindström, Lennart Jacobsson, Mats Dehlin, Karin Bengtsson, Panagiota Drivelegka, Tatiana Zverkova Sandström   +5 more
doaj   +1 more source

Therapeutic Effects of Allopurinol on Left Ventricular Function in Patients with Chronic Heart Failure

پزشکی بالینی ابن سینا, 2010
Introduction & Objective: Heart failure that is a major health problem with increasing incidence with the aging of the population often occurs as a result of ischemia and coronary artery disease.
Alireza Rai, Soozan Khalgh Dost, Hashem Kazerani, Mohammad Rasool Ghadami   +3 more
doaj  

Influence of pharmacogenomic polymorphisms on allopurinol-induced cutaneous adverse drug reactions in Thai patients

BMC Medical Genomics
Background Allopurinol has been causing substantial morbidity and mortality particularly in Asian population by producing cutaneous adverse drug reactions (cADRs).
Gaidganok Sornsamdang, Patompong Satapornpong, Pimonpan Jinda, Thawinee Jantararoungtong, Napatrupron Koomdee, Therdpong Tempark, Jettanong Klaewsongkram, Ticha Rerkpattanapipat, Pawinee Rerknimitr, Papapit Tuchinda, Leena Chularojanamontri, Napatra Tovanabutra, Kumutnart Chanprapaph, Wareeporn Disphanurat, Panlop Chakkavittumrong, Chutika Srisuttiyakorn, Yuttana Srinoulprasert, Shobana John, Mohitosh Biswas, Chonlaphat Sukasem   +19 more
doaj   +1 more source

Assessment of allopurinol use in patients with chronic kidney disease and asymptomatic hyperuricemia: a retrospective cohort study. [PDF]

J Bras Nefrol
Souza MELS, Heringer TA, Schneider APH, Possuelo LG, Valim ARM.   +4 more
europepmc   +1 more source

Benchmarking untargeted metabolomics data quality with allopurinol-induced perturbations. [PDF]

Metabolomics
Vasskog T, Heinsvig PJ, Sharashova E, Hansen T, Myhre TN, Mardal M.   +5 more
europepmc   +1 more source

Polydatin alleviates adenine-induced nephropathy in mice. [PDF]

Ren Fail
Sheng T, Ma T, Jin X, Chen D, Che S, Wang J, Shen J, Shi C, Li Q, Sun Y, Chen D, Xu G.   +11 more
europepmc   +1 more source

Allopurinol has no effect on calcitriol or other CKD-MBD biomarkers: a randomized double-blind study. [PDF]

J Endocr Soc
Costa TE, Lauar JC, Innecchi MLR, Araujo LKRP, Coelho VA, Dos Reis LM, Moysés RMA, Elias RM.   +7 more
europepmc   +1 more source

Uric Acid and Chronic Kidney Disease. [PDF]

Kidney Med
Yadlapalli S, Nekkalapudi DK, Wish JB.
europepmc   +1 more source